Meeting
2022 ASCO Annual Meeting
Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Authors
Nicolas Huyghe
Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
Nicolas Huyghe , Astrid De Cuyper , Isabelle Sinapi , Fazulur Rehaman Vempalli , Darawan Rinchai , Simon Beyaert , Eleonore Verstraelen , Pierre Goffette , Benoît Ghaye , Mélanie Gilet , Aline Van Maanen , Marie-Laure Castella , Bernhard Mlecnik , Javier Carrasco , Jerome Galon , Davide Bedognetti , Marc Van Den Eynde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT03608046
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3595)
DOI
10.1200/JCO.2022.40.16_suppl.3595
Abstract #
3595
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
First Author: Michael Cecchini
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2016 ASCO Annual Meeting
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).
First Author: Emmanuelle Samalin
Poster
2014 Gastrointestinal Cancers Symposium
A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment.
First Author: Vanessa Costa Miranda